2010
Transient Brachial Plexus Palsy: An Unusual Complication of Paravertebral Infusion of Local Anesthetic
D'Souza D, Sondergaard K, Detterbeck FC. Transient Brachial Plexus Palsy: An Unusual Complication of Paravertebral Infusion of Local Anesthetic. The Annals Of Thoracic Surgery 2010, 90: e75-e76. PMID: 20971226, DOI: 10.1016/j.athoracsur.2010.07.071.Peer-Reviewed Original Research
2008
Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 37-45. PMID: 18166839, DOI: 10.1097/jto.0b013e31815e5d9a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCisplatinDeoxycytidineDrug Administration ScheduleFeasibility StudiesFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly-stage non-small cell lung cancerNon-small cell lung cancerCell lung cancerGemcitabine 1000Day 1Neoadjuvant chemotherapyLung cancerResponse ratePathologic complete response rateRandomized phase II trialPhase III settingClinical response rateComplete response ratePerioperative mortality ratePrimary end pointComplete resection ratePhase II trialCarboplatin areaEligible patientsII trialPreoperative regimenResection rateSame regimenUnderwent surgeryMedian survival
2003
A Phase I Study of Gemcitabine and Docetaxel for Advanced Stage Solid Tumors
Poole ME, Bernard SA, Churchel MA, Weissler MC, Calvo B, Cance W, Ollila D, Koruda M, Behrns K, Detterbeck FC. A Phase I Study of Gemcitabine and Docetaxel for Advanced Stage Solid Tumors. Cancer Investigation 2003, 21: 350-354. PMID: 12901280, DOI: 10.1081/cnv-120018225.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityDose of docetaxelPhase IDay 1Solid tumorsAdvanced-stage solid tumorsSignificant nonhematologic toxicityPhase II studyRefractory solid tumorsPhase I studiesM2 i.Nonhematologic toxicityStable diseaseStarting doseII studyPartial responseHypersensitivity reactionsI studiesGastric cancerPrimary siteGemcitabinePatientsDocetaxelDoseConstant dose